Microvesicles (MVs) are small (0.1–1 µm) membrane vesicles released from activated cells.
The surface of MVs can be highly procoagulant due to the presence of the procoagulant …

Abstract Background Microvesicles (MVs) are small double‐membrane encapsulated
particles shed from cells. Case‐control studies have reported elevated plasma levels of …

Microparticles (MPs) are small (0.1–1.0 μm) membrane vesicles constitutively released from
the surface of cells after activation and apoptosis. The clinical research on MPs is hampered …

Cancer patients have a four-to seven-fold increased risk to develop a venous
thromboembolic event. Accumulating evidence from experimental and clinical studies …

Essentials• Cancer patients have a high rate of venous thrombosis (VT) but the underlying
mechanisms are unknown.• Tumor‐derived, tissue factor‐positive microvesicles in platelet …

Introduction. Patients with cancer have a 7-to 10-fold increased risk of developing venous
thromboembolism. Circulating microvesicles could be a useful predictive biomarker for …

Microvesicles (MVs) are small membrane enclosed structures released into the extracellular
space by virtually all cell types. Their composition varies according to the cell origin and the …

BACKGROUND: Cancer is a prothrombotic state, with an increased prevalence of venous
thromboembolism (VTE). Microparticles (MPs) are sub-micron-sized vesicles derived from …

RATIONALE: Analyses of circulating cell membrane-derived microvesicles (MV) have come
under scrutiny as potential diagnostic and prognostic biomarkers of disease. However …

Thrombotic complications have been documented in patients with cancer, and associated
with tumor progression. Cancer patients have an increased level of circulating …